TP53 and pancreatic neuroendocrine tumor: While previous studies have demonstrated that 0–10% of pancreatic NET (G1–G3 combined) and around one-third of G3 pancreatic NET can show mutations in TP53 without RB1 alterations, co-alteration of TP53 and RB1 is rare.